<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01770431</url>
  </required_header>
  <id_info>
    <org_study_id>HE-201101</org_study_id>
    <nct_id>NCT01770431</nct_id>
  </id_info>
  <brief_title>Huaier Granule for Prevention of Recurrence and Metastasis of Hepatocarcinoma After Radical Hepatectomy</brief_title>
  <official_title>A Multicenter, Randomized, Paralleled Control Clinical Study Investigating Huaier Granule for Prevention of Recurrence and Metastasis of Hepatocarcinoma After Radical Hepatectomy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Qidong Gaitianli Medicines Co., Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Huazhong University of Science and Technology</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Qidong Gaitianli Medicines Co., Ltd</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the efficacy and safety of Huaier Granule for prevention of recurrence and
      metastasis of hepatocarcinoma after radical hepatectomy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A Multicenter, Randomized, Paralleled control Clinical Study Investigating Huaier Granule for
      Prevention of Recurrence and Metastasis of Hepatocarcinoma after Radical Hepatectomy,to
      evaluate the efficacy and safety.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2011</start_date>
  <completion_date type="Actual">August 2016</completion_date>
  <primary_completion_date type="Actual">August 2016</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of Recurrence and Metastasis After Hepatectomy</measure>
    <time_frame>Week 94 after took medicine</time_frame>
    <description>At week 94 after took medicine, assess incidence of recurrence and metastasis after hepatectomy.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Postoperative Survival Period</measure>
    <time_frame>Week 94 after took medicine</time_frame>
    <description>Assess Postoperative survival period</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">1044</enrollment>
  <condition>Hepatic Carcinoma</condition>
  <arm_group>
    <arm_group_label>Huaier Granule group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Huaier Granule group; specifications: 20g / bag; manufacturer: Qidong Gaitianli Medicines Co., Ltd..
Administration: the Huaier Granule Electuary should be orally taken from the 15th day after surgery. Usage: Huaier Granule Electuary is continuously taken three times per day, 20g per time, until 96 weeks after surgery or until study termination. The subjects should not take any other anticancer drugs or immunomodulatory agents, except for Huaier Granule.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Bank-control group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Blank-control group, not taking Huaier Granule, other anticancer drugs, or immunomodulatory agents.
During the study, patients who need antiviral therapy, in both the test group and control group, can be treated according to the therapeutic principles.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Huaier Granule</intervention_name>
    <description>Huaier Granule is a traditional Chinese medicine, 20g / time, 3 times/day,Po.</description>
    <arm_group_label>Huaier Granule group</arm_group_label>
    <other_name>Huaier</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age: ≥ 18 and ≤ 75 years, both male and female;

          -  Radical hepatectomy has been performed for hepatocellular carcinoma;

          -  The hepatocellular carcinoma has been confirmed by pathological examination;

          -  Barcelona clinic liver cancer(BCLC) stage A or B;

          -  Not receiving any preoperative anticancer drug;

          -  The liver and kidney function satisfies the following conditions within 15 days after
             surgery (excluding day 15): aspartate aminotransferase(AST), glutamic-oxalacetic
             transaminase(ALT)&lt;3 upper limit of normal(ULN), total bilirubin≤2ULN, serum creatinine
             &lt;1.5 ULN;

          -  Other laboratory tests meet the following requirements within 15 days after surgery
             (excluding day 15): Hb≥9g/dl, platelet count≥60×109/L, absolute neutrophil
             count&gt;1.0×109/L;

          -  The expected survival time ≥ 12 weeks;

          -  The subjects volunteer to sign the informed consent.

        Exclusion Criteria:

          -  Hepatocellular carcinoma patients who received non-radical hepatectomy;

          -  Non-hepatocellular carcinoma patients;

          -  Those with Child-Pugh C;

          -  Pregnant or lactating women;

          -  Those with active bleeding due to various reasons;

          -  Those with HIV infection or AIDS-associated diseases;

          -  Those with severe acute and chronic diseases;

          -  Those with severe diabetes;

          -  Those with serious infectious diseases;

          -  Those who can not take drugs by oral route;

          -  Drug abusers or those with psychological or mental diseases that may interfere with
             study compliance;

          -  Conditions that are considered not suitable for this study investigators
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Xiaoping Chen, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Huazhong University of Science and Technology</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Tongji Hospital Affiliated to Tongji Medical College, Huazhong University of Science and Technology</name>
      <address>
        <city>Wuhan</city>
        <state>Hubei</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>March 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 1, 2013</study_first_submitted>
  <study_first_submitted_qc>January 15, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 17, 2013</study_first_posted>
  <results_first_submitted>January 2, 2017</results_first_submitted>
  <results_first_submitted_qc>May 5, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">October 2, 2017</results_first_posted>
  <last_update_submitted>May 5, 2017</last_update_submitted>
  <last_update_submitted_qc>May 5, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 2, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Huaier Granule;</keyword>
  <keyword>After radical hepatectomy;</keyword>
  <keyword>Prevention of Recurrence and Metastasis;</keyword>
  <keyword>Safety.</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasm Metastasis</mesh_term>
    <mesh_term>Recurrence</mesh_term>
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Patients were recruited from 39 hospitals in China between December 7, 2011 and December 31, 2014. 1044 patients met eligibility criteria and were randomly assigned at a 2:1 ratio: 696 in Huaier group and 348 patients in the blank control group.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Huaier Granule Group</title>
          <description>Huaier Granule group; specifications: 20g / bag; manufacturer: Qidong Gaitianli Medicines Co., Ltd..
Administration: the Huaier Granule Electuary should be orally taken from the 15th day after surgery. Usage: Huaier Granule Electuary is continuously taken three times per day, 20g per time, until 96 weeks after surgery or until study termination. The subjects should not take any other anticancer drugs or immunomodulatory agents, except for Huaier Granule.
Huaier Granule: Huaier Granule is a traditional Chinese medicine, 20g / time, 3 times/day,Po.</description>
        </group>
        <group group_id="P2">
          <title>Bank-control Group</title>
          <description>Blank-control group, not taking Huaier Granule, other anticancer drugs, or immunomodulatory agents.
During the study, patients who need antiviral therapy, in both the test group and control group, can be treated according to the therapeutic principles.
Huaier Granule: Huaier Granule is a traditional Chinese medicine, 20g / time, 3 times/day,Po.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="696"/>
                <participants group_id="P2" count="348"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="686"/>
                <participants group_id="P2" count="316"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="32"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Huaier Granule Group</title>
          <description>Huaier Granule group; specifications: 20g / bag; manufacturer: Qidong Gaitianli Medicines Co., Ltd..
Administration: the Huaier Granule Electuary should be orally taken from the 15th day after surgery. Usage: Huaier Granule Electuary is continuously taken three times per day, 20g per time, until 96 weeks after surgery or until study termination. The subjects should not take any other anticancer drugs or immunomodulatory agents, except for Huaier Granule.
Huaier Granule: Huaier Granule is a traditional Chinese medicine, 20g / time, 3 times/day,Po.</description>
        </group>
        <group group_id="B2">
          <title>Bank-control Group</title>
          <description>Blank-control group, not taking Huaier Granule, other anticancer drugs, or immunomodulatory agents.
During the study, patients who need antiviral therapy, in both the test group and control group, can be treated according to the therapeutic principles.
Huaier Granule: Huaier Granule is a traditional Chinese medicine, 20g / time, 3 times/day,Po.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="686"/>
            <count group_id="B2" value="316"/>
            <count group_id="B3" value="1002"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="573"/>
                    <measurement group_id="B2" value="275"/>
                    <measurement group_id="B3" value="848"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="113"/>
                    <measurement group_id="B2" value="41"/>
                    <measurement group_id="B3" value="154"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="121"/>
                    <measurement group_id="B2" value="61"/>
                    <measurement group_id="B3" value="182"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="565"/>
                    <measurement group_id="B2" value="255"/>
                    <measurement group_id="B3" value="820"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>China</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="686"/>
                    <measurement group_id="B2" value="316"/>
                    <measurement group_id="B3" value="1002"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Number of tumor</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Single tumor</title>
                  <measurement_list>
                    <measurement group_id="B1" value="595"/>
                    <measurement group_id="B2" value="274"/>
                    <measurement group_id="B3" value="869"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Multiple tumors</title>
                  <measurement_list>
                    <measurement group_id="B1" value="91"/>
                    <measurement group_id="B2" value="42"/>
                    <measurement group_id="B3" value="133"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Incidence of Recurrence and Metastasis After Hepatectomy</title>
        <description>At week 94 after took medicine, assess incidence of recurrence and metastasis after hepatectomy.</description>
        <time_frame>Week 94 after took medicine</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Huaier Granule Group</title>
            <description>Huaier Granule group; specifications: 20g / bag; manufacturer: Qidong Gaitianli Medicines Co., Ltd..
Administration: the Huaier Granule Electuary should be orally taken from the 15th day after surgery. Usage: Huaier Granule Electuary is continuously taken three times per day, 20g per time, until 96 weeks after surgery or until study termination. The subjects should not take any other anticancer drugs or immunomodulatory agents, except for Huaier Granule.
Huaier Granule: Huaier Granule is a traditional Chinese medicine, 20g / time, 3 times/day,Po.</description>
          </group>
          <group group_id="O2">
            <title>Bank-control Group</title>
            <description>Blank-control group, not taking Huaier Granule, other anticancer drugs, or immunomodulatory agents.
During the study, patients who need antiviral therapy, in both the test group and control group, can be treated according to the therapeutic principles.
Huaier Granule: Huaier Granule is a traditional Chinese medicine, 20g / time, 3 times/day,Po.</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of Recurrence and Metastasis After Hepatectomy</title>
          <description>At week 94 after took medicine, assess incidence of recurrence and metastasis after hepatectomy.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="686"/>
                <count group_id="O2" value="316"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Recurrence-free</title>
                  <measurement_list>
                    <measurement group_id="O1" value="428"/>
                    <measurement group_id="O2" value="155"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Recurrence</title>
                  <measurement_list>
                    <measurement group_id="O1" value="258"/>
                    <measurement group_id="O2" value="161"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0001</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <param_type>chi-squared</param_type>
            <param_value>14.7315</param_value>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Postoperative Survival Period</title>
        <description>Assess Postoperative survival period</description>
        <time_frame>Week 94 after took medicine</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Huaier Granule Group</title>
            <description>Huaier Granule group; specifications: 20g / bag; manufacturer: Qidong Gaitianli Medicines Co., Ltd..
Administration: the Huaier Granule Electuary should be orally taken from the 15th day after surgery. Usage: Huaier Granule Electuary is continuously taken three times per day, 20g per time, until 96 weeks after surgery or until study termination. The subjects should not take any other anticancer drugs or immunomodulatory agents, except for Huaier Granule.
Huaier Granule: Huaier Granule is a traditional Chinese medicine, 20g / time, 3 times/day,Po.</description>
          </group>
          <group group_id="O2">
            <title>Bank-control Group</title>
            <description>Blank-control group, not taking Huaier Granule, other anticancer drugs, or immunomodulatory agents.
During the study, patients who need antiviral therapy, in both the test group and control group, can be treated according to the therapeutic principles.</description>
          </group>
        </group_list>
        <measure>
          <title>Postoperative Survival Period</title>
          <description>Assess Postoperative survival period</description>
          <units>weeks</units>
          <param>Median</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="686"/>
                <count group_id="O2" value="316"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="75.5" spread="1.15"/>
                    <measurement group_id="O2" value="68.5" spread="1.89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Regression, Cox</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.67</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.55</ci_lower_limit>
            <ci_upper_limit>0.81</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Huaier Granule Group</title>
          <description>Huaier Granule group; specifications: 20g / bag; manufacturer: Qidong Gaitianli Medicines Co., Ltd..
Administration: the Huaier Granule Electuary should be orally taken from the 15th day after surgery. Usage: Huaier Granule Electuary is continuously taken three times per day, 20g per time, until 96 weeks after surgery or until study termination. The subjects should not take any other anticancer drugs or immunomodulatory agents, except for Huaier Granule.
Huaier Granule: Huaier Granule is a traditional Chinese medicine, 20g / time, 3 times/day,Po.</description>
        </group>
        <group group_id="E2">
          <title>Bank-control Group</title>
          <description>Blank-control group, not taking Huaier Granule, other anticancer drugs, or immunomodulatory agents.
During the study, patients who need antiviral therapy, in both the test group and control group, can be treated according to the therapeutic principles.
Huaier Granule: Huaier Granule is a traditional Chinese medicine, 20g / time, 3 times/day,Po.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="686"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="316"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="35" subjects_at_risk="686"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="316"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Product Issues</title>
            <event_list>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="175" subjects_affected="35" subjects_at_risk="686"/>
                <counts group_id="E2" events="72" subjects_affected="6" subjects_at_risk="316"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Xiaoping Chen, Professor</name_or_title>
      <organization>Huazhong University of Science and Technology, Tongji Hospital Affiliated to Tongji Medical College, Huazhong Wuhan, Hubei, China</organization>
      <phone>+86 27 83663400</phone>
      <email>chenxp@medmail.com.cn</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

